Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Roger Tell, Christer Sederholm, Claes Klintenberg, Lars Franksson, Eva Branden, Gunnar Hillerdal, Ulf Lonn, Carl-Johan Linden, Sven-Börje Ewers, Kristina Lamberg, Eva Mrazek, Britta Loden, Anders Sjogren, Thomas Linne, Signe Friesland, Florin Sirzen

Research output: Contribution to journalArticlepeer-review

6 Citations (SciVal)

Abstract

Aim: To evaluate weekly, induction chemotherapy followed by weekly concomitant chemoradiotherapy in a multicentre phase II study of patients with wiresectable stage III non-small cell lung cancer (NSCLC; stage wet IIIB excluded). Patients (aid Methods: Eligible patients received three weekly cycles of paclitaxel 100 mg/m(2) and carboplatin AUC2 followed by six weekly cycles of paclitaxel 60 mg/m(2) and carboplatin AUC2 in combination with thoracic radiotherapy (2 Gy per fraction and day to a total (lose of 60 Gy), Results: Sixty-four patients (40 males and 24 females) with a median age of 63 Years (range, 43-79 years) entered the study. T and N stage were distributed as follows: T1 2 patients (3.2%). T2 10 patients (15.6%), T3 15 patients (23.4%). T4 37 patients (57.8%), N0 10 patients (15.6%). N1 1 patient (1.6%), N2 26 patients (40.6%), N3 26 patients (40.6%), and N missing I patient (1.6%). Seven patients (10.9%) suffered from grade 314 oesophagitis. Grade 112 oesophagitis occurred in 36 patients (56.3%) and pneumonitis grade 112 occurred in 10 patients (15.6%). Sixty-three patients were evaluated on an intent-to-treat basis. The overall response rate was 74.6%. The median time to progression was 247 days and median overall survival was 461 days. According to subgroup analyses, no statistically signicant differences were noted according to gender, age (<65 vs. >= 65 years), perfromance status, histology, or study centre. Conclusion: Induction chemotherapy followed by concurrent chemoradiotherapy with weekly cycles of paclitaxel and carboplatin is feasible and generates moderate toxicity. Efficacy is comparable to other recently published regimens. However, prognosis remains, ill general, poor for this group of patients and further work to develop better therapy is required.
Original languageEnglish
Pages (from-to)2851-2857
JournalAnticancer research
Volume28
Issue number5B
Publication statusPublished - 2008

Subject classification (UKÄ)

  • Cancer and Oncology

Keywords

  • carboplatin
  • paclitaxel
  • induction chemotherapy
  • Non-small cell lung cancer
  • phase II study
  • chemoradiotherapy

Fingerprint

Dive into the research topics of 'Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this